← 產業報告目錄

Peritoneal Dialysis Market by Offering (Peritoneal Dialysis Solution Bags, Machines), Modality (Continuous Ambulatory Peritoneal Dialysis Center(CAPD)), Disease Indication (End-Stage Renal Disease), End User (Hospitals)- Global Forecast to 2031

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2026-07-09頁數 258報告編號 MD9149

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The peritoneal dialysis market is projected to reach USD 14.16 billion by 2031 from USD 10.04 billion in 2026 at a CAGR of 6.0% during the forecast period. Favorable healthcare policies in developed markets have greatly increased access to peritoneal dialysis, as many now offer reimbursement for home-based treatments. In most cases, the United States, Canada, and several other European countries have implemented policies that acknowledge the cost-effectiveness and greater benefits of peritoneal dialysis over in-center hemodialysis for patients. Such policies reduce barriers to treatment by providing reimbursement for a significant portion of PD-associated treatment costs. This could make PD a much more affordable and accessible form of therapy for patients, and reimbursement programs encourage healthcare providers to recommend PD for its flexibility and practicality, especially for those preferring home management of treatment. For instance, in the United States, Medicare's ESRD program encourages wider adoption by providing reimbursements for home dialysis. Likewise, other developed markets are also following and encouraging home dialysis since it reduces hospital admissions, improves patient outcomes, and reduces burdens on healthcare facilities. The financial support that comes with PD has become a reason for the aged and bedridden patients who have been able to live better as a result of reduced immobilization and enhanced personal care. "The end-stage renal disease segment holds the largest market share in the global peritoneal dialysis market and is expected to grow at the highest CAGR during the forecast period." Most healthcare systems promote home dialysis options to reduce hospital visits for end-stage renal disease (ESRD), thereby reducing overall healthcare costs. Health care providers would benefit from home peritoneal dialysis by reducing the need for in-center dialysis, thereby conserving hospital facility capacity and minimizing the problems it poses for both facilities and personnel. Home dialysis will also improve patients' lives by giving them control over their treatment. An added advantage of home-based PD is that it is very economical since it saves transportation costs, minimizes susceptibility to infection, and encourages continuity of care, which makes it an attractive modality for health care systems. "The home care settings segment accounted for the largest market share in the global peritoneal dialysis market and is expected to grow at the highest CAGR during the forecast period." Portable, user-friendly dialysis equipment has further improved the safety and ease of treatment for patients in the home setting. Modern peritoneal dialysis machines are well-designed, with intuitive interfaces, automation, and compact size, making them devices that patients can use with relative ease without relying heavily on medical knowledge. Thus, independent, comfortable home-based dialysis has reduced patients' dependence on healthcare professionals. Safety measures have improved with live monitoring and automatic alarms that enhance outcomes best dealt with early, before dangers occur. With those innovations, patients' confidence in managing their care improved, while treatment compliance generally increased. "North America is expected to witness a substantial growth rate during the forecast period." The peritoneal dialysis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa by region. In 2023, the Asia Pacific region is projected to exhibit the highest CAGR during the forecast period. However, North America accounted for the largest market share of the peritoneal dialysis market in 2025. North America is the largest regional market for peritoneal dialysis, partly because healthcare providers in the region have been trained to manage this treatment. This places them in a better position to ensure that patients requiring the treatment receive a holistic education on how to carry out procedures safely and effectively at home. Moreover, these professionals provide timely interventions through effective monitoring, thereby improving outcomes and reducing complications as much as possible. Specialized training programs and ongoing professional development in the region further underpin quality care. Such professionalism among healthcare professionals has indeed contributed to success in the introduction and spread of peritoneal dialysis in North America. A breakdown of the primary participants (supply-side) for the peritoneal dialysis market referred to in this report is provided below: • By Company Type: Tier 1:34%, Tier 2: 38%, and Tier 3: 28% • By Designation: C-level: 26%, Director Level: 35%, and Others: 39% • By Region: North America: 17%, Europe: 39%, Asia Pacific: 28%, Latin America: 8%, Middle East & Africa: 3%, GCC Countries: 5% Prominent players in the peritoneal dialysis market are market Vantive (US), Fresenius Medical Care AG (Germany), Mozarc Medical (US), Davita Inc. (US), Becton, Dickinson and Company (US), Utah Medical Products, Inc. (US), Terumo Corporation (Japan), Diaverum AB (Sweden), Medionics (Canada), Newsol Technologies (Canada), Apollo Dialysis Pvt Ltd (India), U.S. Renal Care, Inc. (US), Northwest Kidney Centers (US), Relavo (US), Mitra Industries Pvt Ltd (India), JMS Co., Ltd. (Japan), among others. Research Coverage The report evaluates the peritoneal dialysis market and estimates the market size and future growth potential of this market based on various segments, including offerings, modality, disease indication, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies. Reasons to Buy the Report The report will assist market leaders and new entrants with data on the nearest approximations of revenue numbers for the overall market, the peritoneal dialysis market, and the subsegments. The report will assist stakeholders in understanding the competitive landscape and gain further insights into better positioning their businesses and making appropriate go-to-market strategies. The report helps stakeholders understand the market pulse and provides data on key drivers, barriers, and opportunities in the market. This report provides insights into the following points:  Analysis of key drivers Drivers (rising prevalence of chronic kidney diseases, growing prevalence of diabetes and hypertension, and technological advancements and increased investment in R&D) restraints (underutilization of peritoneal dialysis in low-income and lower-middle-income countries (LLMICs)) opportunities (increasing growth opportunities in emerging economies, and surge in demand for home dialysis treatment), and challenges (growing incidence of treated kidney failure, and shortage of skilled nephrologists in low-income and lower-middle-income countries (LLMICs)). • Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the global peritoneal dialysis market • Market Development: Thorough knowledge and analysis of the profitable rising markets by offerings, modality, disease indication, end user, and region. • Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global peritoneal dialysis market • Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the global peritoneal dialysis market
目錄 Table of Contents
1 INTRODUCTION 25 1.1 STUDY OBJECTIVES 25 1.2 MARKET DEFINITION 25 1.2.1 INCLUSIONS AND EXCLUSIONS 26 1.3 STUDY SCOPE 27 1.3.1 SEGMENTS COVERED 27 1.4 YEARS CONSIDERED 28 1.5 CURRENCY USED 28 1.6 STAKEHOLDERS 29 1.7 LIMITATIONS 29 1.8 SUMMARY OF CHANGES 29 2 EXECUTIVE SUMMARY 30 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 30 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND START DEVELOPMENTS 32 2.3 DISRUPTIVE TRENDS SHAPING MARKET 33 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 34 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 35 3 PREMIUM INSIGHTS 36 3.1 PERITONEAL DIALYSIS MARKET OVERVIEW 36 3.2 NORTH AMERICA: PERITONEAL DIALYSIS MARKET, BY PRODUCT AND COUNTRY 37 3.3 PERITONEAL DIALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 38 3.4 PERITONEAL DIALYSIS MARKET, BY REGION 39 3.5 PERITONEAL DIALYSIS MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES 39 4 MARKET OVERVIEW 40 4.1 INTRODUCTION 40 4.2 MARKET DYNAMICS 40 4.2.1 DRIVERS 41 4.2.1.1 Rising prevalence of chronic kidney diseases 41 4.2.1.2 Growing prevalence of diabetes and hypertension 42 4.2.1.3 Technological advancements and increased investment in R&D 43 4.2.2 RESTRAINTS 43 4.2.2.1 Underutilization of peritoneal dialysis in low-income and lower-middle-income countries (LLMICs) 43 4.2.3 OPPORTUNITIES 44 4.2.3.1 Increasing growth opportunities in emerging economies 44 4.2.3.2 Surge in demand for home dialysis treatment 45 4.2.4 CHALLENGES 45 4.2.4.1 Shortage of skilled nephrologists in low-income and lower-middle-income countries (LLMICs) 45 4.2.4.2 High risk of peritonitis as a barrier to peritoneal dialysis adoption 46 4.3 UNMET NEEDS AND WHITE SPACES 46 4.3.1 UNMET NEEDS IN PATIENT MONITORING DEVICES MARKET 47 4.3.2 WHITE SPACE OPPORTUNITIES 47 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 48 4.4.1 INTERCONNECTED MARKETS 48 4.4.2 CROSS-SECTOR OPPORTUNTIES 49 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 50 5 INDUSTRY TRENDS 51 5.1 PORTER’S FIVE FORCES ANALYSIS 51 5.1.1 THREAT OF NEW ENTRANTS 52 5.1.2 THREAT OF SUBSTITUTES 52 5.1.3 BARGAINING POWER OF SUPPLIERS 52 5.1.4 BARGAINING POWER OF BUYERS 52 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 52 5.2 MACROECONOMIC OUTLOOK 53 5.2.1 INTRODUCTION 53 5.2.2 GDP TRENDS AND FORECAST 53 5.2.3 TRENDS IN GLOBAL PERITONEAL DIALYSIS INDUSTRY 55 5.2.4 TRENDS IN GLOBAL HEALTHCARE & RENAL CARE INDUSTRY 55 5.3 SUPPLY CHAIN ANALYSIS 56 5.4 VALUE CHAIN ANALYSIS 57 5.5 ECOSYSTEM ANALYSIS 58 5.6 PRICING ANALYSIS 58 5.6.1 AVERAGE SELLING PRICE TREND, BY PRODUCT 58 5.6.2 AVERAGE SELLING PRICE OF PERITONEAL DIALYSIS PRODUCTS AND CONSUMABLES, BY KEY PLAYER 59 5.6.3 AVERAGE SELLING PRICE TREND OF PERITONEAL DIALYSIS MACHINES, BY REGION 59 5.7 TRADE ANALYSIS 60 5.7.1 IMPORT SCENARIO (HS CODE 9018) 61 5.7.2 EXPORT DATA (HS CODE 9018) 61 5.8 KEY CONFERENCES & EVENTS, 2026–2027 62 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 63 5.10 INVESTMENT AND FUNDING SCENARIO 63 5.11 CASE STUDY ANALYSIS 64 5.11.1 EXPANDING HOME-BASED PERITONEAL DIALYSIS THROUGH REMOTE PATIENT MONITORING 64 5.11.2 ENHANCING HOME PERITONEAL DIALYSIS MANAGEMENT WITH DIGITAL CONNECTIVITY 65 5.11.3 IMPROVING HOME DIALYSIS OUTCOMES THROUGH CONNECTED CARE 65 5.12 IMPACT OF 2025 US TARIFFS – PERITONEAL DIALYSIS MARKET 65 5.12.1 INTRODUCTION 65 5.12.2 KEY TARIFF RATES 66 5.12.3 PRICE IMPACT ANALYSIS 67 5.12.4 IMPACT ON COUNTRIES/REGIONS 68 5.12.4.1 North America 68 5.12.4.2 Europe 68 5.12.4.3 Asia Pacific 68 5.12.5 END-USE INDUSTRY IMPACT 69 5.13 PROCEDURE DATA ANALYSIS 69 5.13.1 PREVALENCE DATA FOR TREATED KIDNEY FAILURE 70 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 74 6.1 KEY EMERGING TECHNOLOGIES 74 6.2 COMPLEMENTARY TECHNOLOGIES 74 6.2.1 REMOTE MONITORING SYSTEMS 75 6.3 TECHNOLOGY/PRODUCT ROADMAP 75 6.3.1 SHORT-TERM (2025–2027) | FOUNDATION & EARLY COMMERCIALIZATION 75 6.3.2 MID-TERM (2027–2030) | EXPANSION & STANDARDIZATION 76 6.3.3 LONG-TERM (2030–2035+) | MASS COMMERCIALIZATION & DISRUPTION 76 6.4 PATENT ANALYSIS 77 6.4.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 78 6.5 FUTURE APPLICATIONS 78 6.5.1 AI-ENABLED REMOTE PERITONEAL DIALYSIS MANAGEMENT & PREDICTIVE CARE 78 6.5.2 SMART PERITONEAL DIALYSIS ECOSYSTEMS 79 6.5.3 ADVANCED PERITONEAL DIALYSIS CONSUMABLES & BIOCOMPATIBLE SOLUTIONS 79 6.6 IMPACT OF AI/GEN AI ON PERITONEAL DIALYSIS MARKET 80 6.6.1 TOP USE CASES AND MARKET POTENTIAL 80 6.6.2 CASE STUDIES OF AI IMPLEMENTATION IN PERITONEAL DIALYSIS MARKET 80 6.6.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 81 6.6.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PERITONEAL DIALYSIS MARKET 82 7 REGULATORY LANDSCAPE 83 7.1 REGIONAL REGULATIONS AND COMPLIANCE 83 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 7.1.2 INDUSTRY STANDARDS 86 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 87 8.1 DECISION-MAKING PROCESS 87 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 87 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 87 8.2.2 KEY BUYING CRITERIA 88 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 89 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 90 8.5 MARKET PROFITABILITY 90 8.5.1 REVENUE POTENTIAL 91 8.5.2 COST DYNAMICS 91 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 91 9 PERITONEAL DIALYSIS MARKET, BY OFFERING 93 9.1 INTRODUCTION 94 9.2 PERITONEAL DIALYSIS PRODUCTS 94 9.2.1 PERITONEAL DIALYSIS SOLUTION BAGS 96 9.2.1.1 High demand for solutions to boost segmental growth 96 9.2.2 PERITONEAL DIALYSIS MACHINES 98 9.2.2.1 Rising prevalence of chronic diseases in emerging economies to boost adoption 98 9.2.3 PERITONEAL DIALYSIS CATHETERS 100 9.2.3.1 Favorable reimbursement policies to support market growth 100 9.2.4 PERITONEAL DIALYSIS TRANSFER SETS 101 9.2.4.1 Product recalls to limit market growth 101 9.2.5 OTHER PERITONEAL DIALYSIS PRODUCTS 102 9.3 PERITONEAL DIALYSIS SERVICES 103 9.3.1 BETTER PRIVACY AND INCREASED COMFORT OF AT-HOME DIALYSIS TREATMENT TO DRIVE MARKET 103 10 PERITONEAL DIALYSIS MARKET, BY MODALITY 105 10.1 INTRODUCTION 106 10.2 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD) 106 10.2.1 SUPERIOR CLEARANCE OF HIGH-MOLECULAR-WEIGHT SUBSTANCES TO DRIVE MARKET 106 10.3 AUTOMATED PERITONEAL DIALYSIS (APD) 107 10.3.1 RISK OF RAPID DECLINE IN RESIDUAL RENAL FUNCTIONS TO LIMIT ADOPTION 107 11 PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION 109 11.1 INTRODUCTION 110 11.2 END-STAGE RENAL DISEASE 110 11.2.1 GROWING GERIATRIC POPULATION AND INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET 110 11.3 ACUTE KIDNEY INJURY 111 11.3.1 INCREASING HOSPITALIZATIONS TO PROPEL MARKET GROWTH 111 11.4 OTHER DISEASES 113 12 PERITONEAL DIALYSIS MARKET, BY END USER 114 12.1 INTRODUCTION 115 12.2 HOME CARE SETTINGS 115 12.2.1 LOWER COST AND SHORTER HOSPITAL STAYS TO AID MARKET GROWTH 115 12.3 HOSPITALS & INDEPENDENT DIALYSIS CENTERS 116 12.3.1 IMPROVED FACILITIES AND INCREASED GOVERNMENT SUPPORT TO DRIVE MARKET 116 12.4 OTHER END USERS 119 13 PERITONEAL DIALYSIS MARKET, BY REGION 120 13.1 INTRODUCTION 121 13.1.1 PERITONEAL DIALYSIS PREVALENCE DATA 121 13.1.2 PERITONEAL DIALYSIS PROCEDURE DATA 122 13.2 NORTH AMERICA 124 13.2.1 US 127 13.2.1.1 US to account for largest market share during study period 127 13.2.2 CANADA 129 13.2.2.1 Shortage of dialysis facilities and increased treatment cost to limit market 129 13.3 EUROPE 131 13.3.1 GERMANY 134 13.3.1.1 Rising number of end-stage renal disease (ESRD) patients to boost market growth 134 13.3.2 UK 136 13.3.2.1 Increased number of new dialysis centers and technological advancements to support market growth 136 13.3.3 FRANCE 138 13.3.3.1 Low cost of peritoneal dialysis and consistent reimbursement policies to drive market growth 138 13.3.4 ITALY 140 13.3.4.1 Increasing research activities and growing patient population with acute renal failure to augment market growth 140 13.3.5 SPAIN 142 13.3.5.1 Favorable reimbursement scenario to boost market growth 142 13.3.6 REST OF EUROPE 145 13.4 ASIA PACIFIC 147 13.4.1 JAPAN 150 13.4.1.1 High prevalence of end-stage renal disease (ESRD) and large geriatric population to support market growth 150 13.4.2 CHINA 152 13.4.2.1 Increasing prevalence of diabetes and hypertension to drive market 152 13.4.3 INDIA 154 13.4.3.1 Favorable government initiatives and high prevalence of kidney disease to fuel market growth 154 13.4.4 AUSTRALIA 156 13.4.4.1 Increasing government initiatives about renal care to support market growth 156 13.4.5 SOUTH KOREA 159 13.4.5.1 Growing geriatric population with chronic kidney disease to propel market growth 159 13.4.6 REST OF ASIA PACIFIC 161 13.5 LATIN AMERICA 163 13.5.1 BRAZIL 165 13.5.1.1 Brazil to account for largest share of Latin American market during forecast period 165 13.5.2 MEXICO 167 13.5.2.1 Increasing patient population and growing middle class population to boost market growth 167 13.5.3 REST OF LATIN AMERICA 169 13.6 MIDDLE EAST & AFRICA 171 13.6.1 GROWING DEMAND FOR CONVENIENT AND ACCESSIBLE RENAL CARE TO PROPEL GROWTH 171 13.7 GCC COUNTRIES 174 13.7.1 HIGHER DISPOSABLE INCOME AND INCREASED GOVERNMENT HEALTHCARE EXPENDITURE TO PROPEL MARKET GROWTH 174 14 COMPETITIVE LANDSCAPE 177 14.1 OVERVIEW 177 14.2 KEY PLAYER STRATEGY/RIGHT TO WIN 177 14.3 REVENUE ANALYSIS 179 14.4 MARKET SHARE ANALYSIS 180 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 182 14.5.1 STARS 182 14.5.2 EMERGING LEADERS 182 14.5.3 PERVASIVE PLAYERS 183 14.5.4 PARTICIPANTS 183 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 184 14.5.5.1 Company footprint 184 14.5.5.2 Region footprint 185 14.5.5.3 Offering footprint 186 14.5.5.4 Modality footprint 187 14.5.5.5 Disease indication footprint 188 14.5.5.6 End-user footprint 189 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 189 14.6.1 PROGRESSIVE COMPANIES 189 14.6.2 RESPONSIVE COMPANIES 189 14.6.3 DYNAMIC COMPANIES 190 14.6.4 STARTING BLOCKS 190 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 191 14.6.5.1 Detailed list of key start-up/SME players 191 14.6.5.2 Competitive benchmarking of key startup/SME players 191 14.7 COMPANY VALUATION & FINANCIAL METRICS 192 14.8 BRAND/PRODUCT COMPARISON 193 14.9 COMPETITIVE SCENARIO 194 14.9.1 PRODUCT APPROVALS 194 14.9.2 DEALS 194 14.9.3 EXPANSIONS 195 14.9.3.1 Other developments 196 15 COMPANY PROFILES 197 15.1 KEY PLAYERS 197 15.1.1 FRESENIUS MEDICAL CARE AG 197 15.1.1.1 Business overview 197 15.1.1.2 Products & services offered 198 15.1.1.3 Recent developments 200 15.1.1.3.1 Deals 200 15.1.1.4 MnM view 200 15.1.1.4.1 Right to win 200 15.1.1.4.2 Strategic choices 200 15.1.1.4.3 Weaknesses & competitive threats 200 15.1.2 VANTIVE 201 15.1.2.1 Business overview 201 15.1.2.2 Products & services offered 202 15.1.2.3 Recent developments 203 15.1.2.3.1 Deals 203 15.1.2.4 MnM view 203 15.1.2.4.1 Right to win 203 15.1.2.4.2 Strategic choices 203 15.1.2.4.3 Weaknesses & competitive threats 204 15.1.3 DAVITA INC. 205 15.1.3.1 Business overview 205 15.1.3.2 Products & services offered 206 15.1.3.3 Recent developments 206 15.1.3.3.1 Deals 206 15.1.3.3.2 Expansions 206 15.1.3.4 Other developments 207 15.1.3.5 MnM view 207 15.1.3.5.1 Right to win 207 15.1.3.5.2 Strategic choices 207 15.1.3.5.3 Weaknesses & competitive threats 207 15.1.4 TERUMO CORPORATION 208 15.1.4.1 Business overview 208 15.1.4.2 Products & services offered 209 15.1.4.3 Recent developments 209 15.1.4.3.1 Product approvals 209 15.1.4.3.2 Deals 210 15.1.4.3.3 Expansions 210 15.1.4.4 MnM view 210 15.1.4.4.1 Right to win 210 15.1.4.4.2 Strategic choices 210 15.1.4.4.3 Weaknesses & competitive threats 211 15.1.5 BECTON, DICKINSON AND COMPANY 212 15.1.5.1 Business overview 212 15.1.5.2 Products & services offered 214 15.1.5.3 Recent developments 214 15.1.5.3.1 Expansions 214 15.1.5.4 MnM view 215 15.1.5.4.1 Right to win 215 15.1.5.4.2 Strategic choices 215 15.1.5.4.3 Weaknesses & competitive threats 215 15.1.6 UTAH MEDICAL PRODUCTS, INC. 216 15.1.6.1 Business overview 216 15.1.6.2 Products & services offered 218 15.1.7 MOZARC MEDICAL 219 15.1.7.1 Business overview 219 15.1.7.2 Products & services offered 220 15.1.8 DIAVERUM AB 221 15.1.8.1 Business overview 221 15.1.8.2 Products & services offered 221 15.1.9 MEDIONICS 222 15.1.9.1 Business overview 222 15.1.9.2 Products & services offered 222 15.1.10 NEWSOL TECHNOLOGIES INC. 224 15.1.10.1 Business overview 224 15.1.10.2 Products & services offered 224 15.1.11 APOLLO DIALYSIS PVT. LTD. 225 15.1.11.1 Business overview 225 15.1.11.2 Products & services offered 225 15.1.12 U.S. RENAL CARE, INC. 226 15.1.12.1 Business overview 226 15.1.12.2 Products & services offered 226 15.1.13 NORTHWEST KIDNEY CENTERS 227 15.1.13.1 Business overview 227 15.1.13.2 Products & services offered 227 15.1.13.3 Recent developments 228 15.1.13.3.1 Deals 228 15.1.13.3.2 Expansions 228 15.1.14 RELAVO 229 15.1.14.1 Business overview 229 15.1.14.2 Products & services offered 229 15.1.15 MITRA INDUSTRIES PVT. LTD. 230 15.1.15.1 Business overview 230 15.1.15.2 Products & services offered 230 15.2 OTHER PLAYERS 232 15.2.1 JMS CO., LTD. 232 15.2.2 AMECATH 232 15.2.3 POLYMEDICURE 233 15.2.4 HUAREN PHARMACEUTICAL 233 15.2.5 AWAK TECHNOLOGIES 234 15.2.6 INNOVATIVE RENAL CARE 234 15.2.7 ROMSONS 235 15.2.8 SSEM MTHEMBU MEDICAL (PTY) LTD. 235 15.2.9 RENAX BIOMEDICAL TECHNOLOGY CO., LTD. 236 15.2.10 ADVIN HEALTH CARE 236 16 RESEARCH METHODOLOGY 237 16.1 RESEARCH DATA 237 16.1.1 SECONDARY DATA 238 16.1.2 PRIMARY DATA 240 16.2 MARKET SIZE ESTIMATION 242 16.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 242 16.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS 244 16.2.3 USAGE-BASED MARKET ESTIMATION 244 16.2.4 PRIMARY RESEARCH VALIDATION 247 16.3 GROWTH FORECAST ESTIMATION 247 16.4 DATA TRIANGULATION 249 16.5 STUDY ASSUMPTIONS 250 16.6 RISK ASSESSMENT 250 16.7 RESEARCH LIMITATIONS 250 17 APPENDIX 251 17.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 254 17.2 CUSTOMIZATION OPTIONS 256 17.3 RELATED REPORTS 256 17.4 AUTHOR DETAILS 257
圖表清單 List of Tables & Figures
TABLE 1 INCLUSIONS AND EXCLUSIONS 26 TABLE 2 STANDARD USD CURRENCY CONVERSION RATES 28 TABLE 3 NUMBER OF PEOPLE AGED 65 YEARS OR OVER, BY REGION, 2022 VS. 2050 42 TABLE 4 UTILIZATION OF KIDNEY REPLACEMENT THERAPIES (PERITONEAL DIALYSIS VS. HEMODIALYSIS) 44 TABLE 5 COST OF KIDNEY REPLACEMENT THERAPIES 44 TABLE 6 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 50 TABLE 7 PERITONEAL DIALYSIS MARKET: PORTER’S FIVE FORCES 51 TABLE 8 GDP PERCENTAGE CHANGE, BY KEY COUNTRY, 2021–2030 53 TABLE 9 AVERAGE SELLING PRICE OF PERITONEAL DIALYSIS PRODUCTS AND CONSUMABLES, BY KEY PLAYER, 2025 (USD) 59 TABLE 10 AVERAGE SELLING PRICE TREND OF PERITONEAL DIALYSIS MACHINES, BY REGION, 2023–2025 (USD) 60 TABLE 11 IMPORT DATA FOR PERITONEAL DIALYSIS PRODUCTS UNDER HS CODE 9018, BY COUNTRY, 2021–2025 (USD THOUSAND) 61 TABLE 12 EXPORT DATA FOR PERITONEAL DIALYSIS UNDER HS CODE 9018, BY COUNTRY, 2021–2025 (USD THOUSAND) 62 TABLE 13 PERITONEAL DIALYSIS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, 2026–2027 62 TABLE 14 US-ADJUSTED RECIPROCAL TARIFF RATES 66 TABLE 15 KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR PERITONEAL DIALYSIS 67 TABLE 16 PREVALENCE DATA, BY COUNTRY, 2021–2023 (PMP) 70 TABLE 17 NUMBER OF PERITONEAL DIALYSIS PATIENTS, BY REGION, 2019–2023 71 TABLE 18 NUMBER OF PERITONEAL DIALYSIS PATIENTS, BY REGION, 2024–2029 71 TABLE 19 PROCEDURE DATA FOR PERITONEAL DIALYSIS, BY COUNTRY, 2019–2023 72 TABLE 20 PROCEDURE DATA FOR PERITONEAL DIALYSIS, BY COUNTRY, 2024–2029 73 TABLE 21 TOP USE CASES AND MARKET POTENTIAL 80 TABLE 22 PERITONEAL DIALYSIS MARKET: CASE STUDIES RELATED TO AI IMPLEMENTATION 80 TABLE 23 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 81 TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 84 TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85 TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85 TABLE 28 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85 TABLE 29 GLOBAL STANDARDS IN PERITONEAL DIALYSIS MARKET 86 TABLE 30 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR PERITONEAL DIALYSIS PRODUCTS 88 TABLE 31 BUYING CRITERIA FOR PERITONEAL DIALYSIS PRODUCTS 89 TABLE 32 PERITONEAL DIALYSIS MARKET: UNMET NEEDS/END-USER EXPECTATIONS 90 TABLE 33 PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 94 TABLE 34 PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 95 TABLE 35 PERITONEAL DIALYSIS PRODUCTS MARKET, BY REGION/COUNTRY, 2024–2031 (USD MILLION) 95 TABLE 36 AVERAGE VOLUME OF EXCHANGE, BY REGION, 2021–2025 (MILLION LITERS) 96 TABLE 37 AVERAGE VOLUME OF EXCHANGE, BY REGION, 2027–2031 (MILLION LITERS) 97 TABLE 38 PERITONEAL DIALYSIS SOLUTION BAGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 97 TABLE 39 PERITONEAL DIALYSIS SOLUTION BAGS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 98 TABLE 40 PERITONEAL DIALYSIS MACHINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 99 TABLE 41 PERITONEAL DIALYSIS MACHINES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 100 TABLE 42 PERITONEAL DIALYSIS CATHETERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 101 TABLE 43 PERITONEAL DIALYSIS TRANSFER SETS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 102 TABLE 44 OTHER PERITONEAL DIALYSIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 103 TABLE 45 PERITONEAL DIALYSIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 104 TABLE 46 PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 106 TABLE 47 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD) MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 107 TABLE 48 AMBULATORY PERITONEAL DIALYSIS (APD) MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 108 TABLE 49 PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 110 TABLE 50 PERITONEAL DIALYSIS MARKET FOR END-STAGE RENAL DISEASE, BY REGION, 2024–2031 (USD MILLION) 111 TABLE 51 PERITONEAL DIALYSIS MARKET FOR ACUTE KIDNEY INJURY, BY REGION, 2024–2031 (USD MILLION) 112 TABLE 52 PERITONEAL DIALYSIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 113 TABLE 53 PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 115 TABLE 54 PERITONEAL DIALYSIS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 116 TABLE 55 PERITONEAL DIALYSIS MARKET FOR HOSPITALS & INDEPENDENT DIALYSIS CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 118 TABLE 56 PERITONEAL DIALYSIS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 119 TABLE 57 PERITONEAL DIALYSIS PREVALENCE DATA, BY COUNTRY, 2021–2025 121 TABLE 58 PERITONEAL DIALYSIS PREVALENCE DATA, BY COUNTRY, 2026–2031 122 TABLE 59 PERITONEAL DIALYSIS PROCEDURE DATA, BY REGION, 2021–2025 (MILLION PROCEDURES) 122 TABLE 60 PERITONEAL DIALYSIS PROCEDURE DATA, BY REGION, 2025–2031 (MILLION PROCEDURES) 123 TABLE 61 PERITONEAL DIALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION) 123 TABLE 62 NORTH AMERICA: PERITONEAL DIALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 125 TABLE 63 NORTH AMERICA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 125 TABLE 64 NORTH AMERICA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 125 TABLE 65 NORTH AMERICA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 126 TABLE 66 NORTH AMERICA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 126 TABLE 67 NORTH AMERICA: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 126 TABLE 68 US: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 127 TABLE 69 US: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 128 TABLE 70 US: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 128 TABLE 71 US: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 128 TABLE 72 US: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 129 TABLE 73 CANADA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 130 TABLE 74 CANADA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 130 TABLE 75 CANADA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 130 TABLE 76 CANADA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 131 TABLE 77 CANADA: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 131 TABLE 78 EUROPE: PERITONEAL DIALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 79 EUROPE: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 132 TABLE 80 EUROPE: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 132 TABLE 81 EUROPE: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 133 TABLE 82 EUROPE: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 133 TABLE 83 EUROPE: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 133 TABLE 84 GERMANY: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 134 TABLE 85 GERMANY: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 135 TABLE 86 GERMANY: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 135 TABLE 87 GERMANY: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 135 TABLE 88 GERMANY: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 136 TABLE 89 UK: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 136 TABLE 90 UK: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 137 TABLE 91 UK: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 137 TABLE 92 UK: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 137 TABLE 93 UK: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 138 TABLE 94 FRANCE: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 139 TABLE 95 FRANCE: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 139 TABLE 96 FRANCE: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 139 TABLE 97 FRANCE: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 140 TABLE 98 FRANCE: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 140 TABLE 99 ITALY: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 141 TABLE 100 ITALY: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 141 TABLE 101 ITALY: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 141 TABLE 102 ITALY: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 142 TABLE 103 ITALY: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 142 TABLE 104 SPAIN: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 143 TABLE 105 SPAIN: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 143 TABLE 106 SPAIN: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 143 TABLE 107 SPAIN: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 144 TABLE 108 SPAIN: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 144 TABLE 109 REST OF EUROPE: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 145 TABLE 110 REST OF EUROPE: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 145 TABLE 111 REST OF EUROPE: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 146 TABLE 112 REST OF EUROPE: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 146 TABLE 113 REST OF EUROPE: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 146 TABLE 114 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 115 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 148 TABLE 116 ASIA PACIFIC: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 148 TABLE 117 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 149 TABLE 118 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 149 TABLE 119 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 149 TABLE 120 JAPAN: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 150 TABLE 121 JAPAN: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 151 TABLE 122 JAPAN: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 151 TABLE 123 JAPAN: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 151 TABLE 124 JAPAN: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 152 TABLE 125 CHINA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 153 TABLE 126 CHINA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 153 TABLE 127 CHINA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 153 TABLE 128 CHINA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 154 TABLE 129 CHINA: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 154 TABLE 130 INDIA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 155 TABLE 131 INDIA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 155 TABLE 132 INDIA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 155 TABLE 133 INDIA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 156 TABLE 134 INDIA: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 156 TABLE 135 AUSTRALIA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 157 TABLE 136 AUSTRALIA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 157 TABLE 137 AUSTRALIA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 158 TABLE 138 AUSTRALIA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 158 TABLE 139 AUSTRALIA: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 158 TABLE 140 SOUTH KOREA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 159 TABLE 141 SOUTH KOREA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 159 TABLE 142 SOUTH KOREA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 160 TABLE 143 SOUTH KOREA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 160 TABLE 144 SOUTH KOREA: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 160 TABLE 145 REST OF ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 161 TABLE 146 REST OF ASIA PACIFIC: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 161 TABLE 147 REST OF ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 162 TABLE 148 REST OF ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 162 TABLE 149 REST OF ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 162 TABLE 150 LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 151 LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 163 TABLE 152 LATIN AMERICA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 164 TABLE 153 LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 164 TABLE 154 LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 164 TABLE 155 LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 165 TABLE 156 BRAZIL: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 165 TABLE 157 BRAZIL: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 166 TABLE 158 BRAZIL: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 166 TABLE 159 BRAZIL: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 166 TABLE 160 BRAZIL: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 167 TABLE 161 MEXICO: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 167 TABLE 162 MEXICO: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 168 TABLE 163 MEXICO: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 168 TABLE 164 MEXICO: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 168 TABLE 165 MEXICO: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 169 TABLE 166 REST OF LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 169 TABLE 167 REST OF LATIN AMERICA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 170 TABLE 168 REST OF LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 170 TABLE 169 REST OF LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 170 TABLE 170 REST OF LATIN AMERICA: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 171 TABLE 171 MIDDLE EAST & AFRICA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 172 TABLE 172 MIDDLE EAST & AFRICA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 172 TABLE 173 MIDDLE EAST & AFRICA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 173 TABLE 174 MIDDLE EAST & AFRICA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 173 TABLE 175 MIDDLE EAST & AFRICA: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 173 TABLE 176 GCC COUNTRIES: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 174 TABLE 177 GCC COUNTRIES: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 175 TABLE 178 GCC COUNTRIES: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024–2031 (USD MILLION) 175 TABLE 179 GCC COUNTRIES: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 176 TABLE 180 GCC COUNTRIES: PERITONEAL DIALYSIS MARKET, BY END USER, 2024–2031 (USD MILLION) 176 TABLE 181 KEY DEVELOPMENTS IN PERITONEAL DIALYSIS MARKET, JANUARY 2021–JULY 2026 177 TABLE 182 PERITONEAL DIALYSIS MARKET: DEGREE OF COMPETITION 181 TABLE 183 PERITONEAL DIALYSIS MARKET: REGION FOOTPRINT, 2025 185 TABLE 184 PERITONEAL DIALYSIS MARKET: OFFERING FOOTPRINT, 2025 186 TABLE 185 PERITONEAL DIALYSIS MARKET: MODALITY FOOTPRINT, 2025 187 TABLE 186 PERITONEAL DIALYSIS MARKET: DISEASE INDICATION FOOTPRINT, 2025 188 TABLE 187 PERITONEAL DIALYSIS MARKET: END-USER FOOTPRINT, 2025 189 TABLE 188 PERITONEAL DIALYSIS MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS, 2025 191 TABLE 189 PERITONEAL DIALYSIS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/ SME PLAYERS, 2025 191 TABLE 190 PERITONEAL DIALYSIS MARKET: PRODUCT APPROVALS, JANUARY 2021–JULY 2026 194 TABLE 191 PERITONEAL DIALYSIS MARKET: DEALS, JANUARY 2021–JULY 2026 194 TABLE 192 PERITONEAL DIALYSIS MARKET: EXPANSIONS, JANUARY 2021–JULY 2026 195 TABLE 193 PERITONEAL DIALYSIS MARKET: OTHER DEVELOPMENTS, JANUARY 2021–JULY 2026 196 TABLE 194 FRESENIUS MEDICAL CARE AG: COMPANY OVERVIEW 197 TABLE 195 FRESENIUS MEDICAL CARE AG: PRODUCTS & SERVICES OFFERED 198 TABLE 196 FRESENIUS MEDICAL CARE AG: DEALS 200 TABLE 197 VANTIVE: COMPANY OVERVIEW 201 TABLE 198 VANTIVE: PRODUCTS & SERVICES OFFERED 202 TABLE 199 VANTIVE: DEALS 203 TABLE 200 DAVITA INC.: COMPANY OVERVIEW 205 TABLE 201 DAVITA INC.: PRODUCTS & SERVICES OFFERED 206 TABLE 202 DAVITA INC.: DEALS 206 TABLE 203 DAVITA INC.: EXPANSIONS 206 TABLE 204 DAVITA INC.: OTHER DEVELOPMENTS 207 TABLE 205 TERUMO CORPORATION: COMPANY OVERVIEW 208 TABLE 206 TERUMO CORPORATION: PRODUCTS & SERVICES OFFERED 209 TABLE 207 TERUMO CORPORATION: PRODUCT APPROVALS 209 TABLE 208 TERUMO CORPORATION: DEALS 210 TABLE 209 TERUMO CORPORATION: EXPANSIONS 210 TABLE 210 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 212 TABLE 211 BECTON, DICKINSON AND COMPANY: PRODUCTS & SERVICES OFFERED 214 TABLE 212 BECTON, DICKINSON AND COMPANY: EXPANSIONS 214 TABLE 213 UTAH MEDICAL PRODUCTS, INC.: COMPANY OVERVIEW 216 TABLE 214 UTAH MEDICAL PRODUCTS, INC.: PRODUCTS & SERVICES OFFERED 218 TABLE 215 MOZARC MEDICAL: COMPANY OVERVIEW 219 TABLE 216 MOZARC MEDICAL: PRODUCTS & SERVICES OFFERED 220 TABLE 217 DIAVERUM AB: COMPANY OVERVIEW 221 TABLE 218 DIAVERUM AB: PRODUCTS & SERVICES OFFERED 221 TABLE 219 MEDIONICS: COMPANY OVERVIEW 222 TABLE 220 MEDIONICS: PRODUCTS & SERVICES OFFERED 222 TABLE 221 NEWSOL TECHNOLOGIES INC.: COMPANY OVERVIEW 224 TABLE 222 NEWSOL TECHNOLOGIES INC.: PRODUCTS & SERVICES OFFERED 224 TABLE 223 APOLLO DIALYSIS PVT. LTD.: COMPANY OVERVIEW 225 TABLE 224 APOLLO DIALYSIS PVT. LTD.: PRODUCTS & SERVICES OFFERED 225 TABLE 225 U.S. RENAL CARE, INC.: COMPANY OVERVIEW 226 TABLE 226 U.S. RENAL CARE, INC.: PRODUCTS & SERVICES OFFERED 226 TABLE 227 NORTHWEST KIDNEY CENTERS: COMPANY OVERVIEW 227 TABLE 228 NORTHWEST KIDNEY CENTERS: PRODUCTS & SERVICES OFFERED 227 TABLE 229 NORTHWEST KIDNEY CENTERS: DEALS 228 TABLE 230 NORTHWEST KIDNEY CENTERS: EXPANSIONS 228 TABLE 231 RELAVO: COMPANY OVERVIEW 229 TABLE 232 RELAVO: PRODUCTS & SERVICES OFFERED 229 TABLE 233 MITRA INDUSTRIES PVT. LTD.: COMPANY OVERVIEW 230 TABLE 234 MITRA INDUSTRIES PVT. LTD.: PRODUCTS & SERVICES OFFERED 230 TABLE 235 STUDY ASSUMPTIONS 250 TABLE 236 RISK ASSESSMENT 250 FIGURE 1 PERITONEAL DIALYSIS MARKET SEGMENTATION 27 FIGURE 2 STUDY YEARS CONSIDERED 28 FIGURE 3 KEY INSIGHTS AND MARKET HIGHLIGHTS 30 FIGURE 4 PERITONEAL DIALYSIS MARKET, 2024–2031 (USD MILLION) 31 FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PERITONEAL DIALYSIS MARKET 32 FIGURE 6 DISRUPTIVE TRENDS IMPACTING GROWTH OF PERITONEAL DIALYSIS MARKET 33 FIGURE 7 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS IN PERITONEAL DIALYSIS MARKET, 2026 34 FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 35 FIGURE 9 STRINGENT REGULATORY FRAMEWORK TO DRIVE MARKET GROWTH 36 FIGURE 10 HOMECARE SEGMENT TO ACCOUNT FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2025 37 FIGURE 11 INDIA TO REGISTER HIGHEST GROWTH RATE FROM 2026 TO 2031 38 FIGURE 12 NORTH AMERICA TO ACCOUNT FOR LARGEST MARKET SHARE TILL 2031 39 FIGURE 13 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATE 39 FIGURE 14 PERITONEAL DIALYSIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 40 FIGURE 15 CANADA: NUMBER OF END-STAGE RENAL DISEASE PATIENTS, BY AGE GROUP (2025) 41 FIGURE 16 US: REPORTED CAUSES OF END-STAGE RENAL DISEASE (2025) 42 FIGURE 17 SHORTAGES OF NEPHROLOGISTS IN LOW-INCOME AND LOWER-MIDDLE-INCOME COUNTRIES (LLMICS) 46 FIGURE 18 PERITONEAL DIALYSIS MARKET: PORTER’S FIVE FORCES ANALYSIS 51 FIGURE 19 PERITONEAL DIALYSIS MARKET: SUPPLY CHAIN ANALYSIS 57 FIGURE 20 PERITONEAL DIALYSIS MARKET: VALUE CHAIN ANALYSIS 57 FIGURE 21 PERITONEAL DIALYSIS MARKET: ECOSYSTEM ANALYSIS 58 FIGURE 22 AVERAGE SELLING PRICE TREND OF PERITONEAL DIALYSIS MACHINES, BY REGION, 2023–2025 (USD) 60 FIGURE 23 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 63 FIGURE 24 PERITONEAL DIALYSIS MARKET: INVESTMENT & FUNDING SCENARIO, 2019–2023 64 FIGURE 25 NUMBER OF PATENTS PUBLISHED, JANUARY 2016─JULY 2026 77 FIGURE 26 TOP APPLICANT COUNTRIES/REGIONS FOR PERITONEAL DIALYSIS (JANUARY 2016− JULY 2026) 78 FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PERITONEAL DIALYSIS PRODUCTS 88 FIGURE 28 KEY BUYING CRITERIA FOR PERITONEAL DIALYSIS PRODUCTS 88 FIGURE 29 NORTH AMERICA: PERITONEAL DIALYSIS MARKET SNAPSHOT 124 FIGURE 30 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET SNAPSHOT 147 FIGURE 31 REVENUE ANALYSIS OF TOP PLAYERS IN PERITONEAL DIALYSIS MARKET, 2023–2025 (USD MILLION) 179 FIGURE 32 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025 180 FIGURE 33 PERITONEAL DIALYSIS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 183 FIGURE 34 PERITONEAL DIALYSIS MARKET: COMPANY FOOTPRINT, 2025 184 FIGURE 35 PERITONEAL DIALYSIS MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2025 190 FIGURE 36 EV/EBITDA OF KEY VENDORS, 2026 192 FIGURE 37 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2026 192 FIGURE 38 BRAND/PRODUCT COMPARATIVE ANALYSIS 193 FIGURE 39 FRESENIUS MEDICAL CARE AG: COMPANY SNAPSHOT 198 FIGURE 40 DAVITA INC.: COMPANY SNAPSHOT 205 FIGURE 41 TERUMO CORPORATION: COMPANY SNAPSHOT 208 FIGURE 42 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 213 FIGURE 43 UTAH MEDICAL PRODUCTS, INC.: COMPANY SNAPSHOT 217 FIGURE 44 RESEARCH DESIGN: PERITONEAL DIALYSIS MARKET 237 FIGURE 45 INDICATIVE LIST OF SECONDARY SOURCES 239 FIGURE 46 LIST OF KEY PRIMARY SOURCES 240 FIGURE 47 KEY INDUSTRY INSIGHTS 241 FIGURE 48 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 241 FIGURE 49 BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE, DESIGNATION, AND REGION 242 FIGURE 50 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 243 FIGURE 51 REVENUE SHARE ANALYSIS ILLUSTRATION 243 FIGURE 52 SUPPLY-SIDE MARKET SIZE ESTIMATION: PERITONEAL DIALYSIS MARKET (2025) 244 FIGURE 53 ESTIMATION OF PERITONEAL DIALYSIS PROCEDURES, BY COUNTRY/REGION 245 FIGURE 54 MARKET SIZE ESTIMATION: PERITONEAL DIALYSIS MARKET, BY PRODUCT UTILIZATION METHODOLOGY 245 FIGURE 55 MARKET SIZE ESTIMATION: PERITONEAL DIALYSIS SERVICES MARKET, BY REVENUE MAPPING METHODOLOGY 246 FIGURE 56 PERITONEAL DIALYSIS: AVERAGE VOLUME EXCHANGE ESTIMATION MODEL 246 FIGURE 57 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2026–2031) 248 FIGURE 58 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 248 FIGURE 59 DATA TRIANGULATION METHODOLOGY 249

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們